Our team will work with you to set realistic expectations and support you in understanding that Tirzepatide is a tool to assist in your weight loss journey, not a substitute for fundamental lifestyle changes
Phase 2 trials showed up to 24% body weight reduction at the highest dose, and Phase 3 data from the TRIUMPH program pushed that number even higher, reaching 28.7% in participants with obesity and knee osteoarthritis
Brittany Weber, Director of the Cardio-Rheumatology/ Cardio-Dermatology Program at the University of Texas Southwestern
Evidence that the major degradation product of glucose-dependent insulinotropic polypeptide, GIP(3-42), is a GIP receptor antagonist in vivo
Bertilsson G, Patrone C, Zachrisson O, Andersson A, Dannaeus K, Heidrich J, et al
Your vision is precious, and were here to help you protect it